Sugi Predict

Sugi Predict / Targets / INO80C

INO80C

INO80 complex subunit C · Q6PI98 · INO80C on Sugi Atlas →

0 patent compounds predicted against INO80C, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to INO80C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer PHASE2ACTIVE_NOT_RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
INVAC-1 Anti-Cancer hTERT DNA Immunotherapy PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic nanCOMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients nanACTIVE_NOT_RECRUITING
Precision High-Intensity Training Through Epigenetics (PHITE) nanCOMPLETED
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors nanWITHDRAWN
Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
The Phenotyping and Genotyping of Taiwanese Patients With Obstructive Sleep Apnea nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a INO80C binder may also engage these)

ProteinNameSimilarity
Q5BJY3 — 1.000 Q5BJY3 →
Q8BHA0 — 0.999 Q8BHA0 →
Q9D902 — 0.962 Q9D902 →
Q02614 — 0.959 Q02614 →
A2VDN6 — 0.959 A2VDN6 →
Q5JSJ4 — 0.958 Q5JSJ4 →
SAP30BP SAP30-binding protein 0.957 landscape →
Q80ZQ5 — 0.957 Q80ZQ5 →
P29540 — 0.956 P29540 →
Q5RDF5 — 0.955 Q5RDF5 →
Q86Y37 — 0.955 Q86Y37 →
Q9HCE3 — 0.954 Q9HCE3 →
YTHDF2 YTH domain-containing family protein 2 0.954 landscape →
Q4R5D9 — 0.954 Q4R5D9 →
Q8VYN2 — 0.954 Q8VYN2 →
Q13542 — 0.954 Q13542 →
Q01826 — 0.954 Q01826 →
Q2YDP3 — 0.953 Q2YDP3 →
Q4R8N2 — 0.953 Q4R8N2 →
Q8BND4 — 0.953 Q8BND4 →
Q9MB58 — 0.953 Q9MB58 →
Q2KJF9 — 0.952 Q2KJF9 →
O95628 — 0.952 O95628 →
Q5F3N6 — 0.952 Q5F3N6 →
Q6Z746 — 0.951 Q6Z746 →
SF3A1 Splicing factor 3A subunit 1 0.951 landscape →
O46606 — 0.951 O46606 →
Q5R6F1 — 0.950 Q5R6F1 →
Q80U70 — 0.950 Q80U70 →
Q14919 — 0.950 Q14919 →